€
2.60
May 13
Business Description
HLS Therapeutics Inc
NAICS : 325412
SIC : 3741
ISIN : CA40390B1094
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.25 | |||||
Equity-to-Asset | 0.47 | |||||
Debt-to-Equity | 0.9 | |||||
Debt-to-EBITDA | 6.75 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -0.57 | |||||
Beneish M-Score | -3.31 | |||||
WACC vs ROIC |
Growth Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5 | |||||
3-Year EBITDA Growth Rate | -17 | |||||
3-Year EPS without NRI Growth Rate | -5 | |||||
3-Year Book Growth Rate | -15.6 | |||||
Future 3-5Y Total Revenue Growth Rate | 11.39 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 9.53 | |||||
9-Day RSI | 18.95 | |||||
14-Day RSI | 28.94 | |||||
6-1 Month Momentum % | 15.97 | |||||
12-1 Month Momentum % | 11.33 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.65 | |||||
Quick Ratio | 1.29 | |||||
Cash Ratio | 0.82 | |||||
Days Inventory | 459.5 | |||||
Days Sales Outstanding | 54.79 | |||||
Days Payable | 632.27 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.26 | |||||
3-Year Dividend Growth Rate | -19.5 | |||||
5-Year Yield-on-Cost % | 2.09 | |||||
3-Year Average Share Buyback Ratio | -0.2 | |||||
Shareholder Yield % | 4.3 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 87.92 | |||||
Operating Margin % | -16.43 | |||||
Net Margin % | -43.59 | |||||
FCF Margin % | 20.69 | |||||
ROE % | -24.7 | |||||
ROA % | -12.17 | |||||
ROIC % | -5.22 | |||||
ROC (Joel Greenblatt) % | -518.34 | |||||
ROCE % | -9.67 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.49 | |||||
PB Ratio | 0.96 | |||||
Price-to-Free-Cash-Flow | 5.95 | |||||
Price-to-Operating-Cash-Flow | 5.95 | |||||
EV-to-EBIT | -8.4 | |||||
EV-to-EBITDA | 12.36 | |||||
EV-to-Revenue | 2.53 | |||||
EV-to-Forward-Revenue | 2.47 | |||||
EV-to-FCF | 10.09 | |||||
Price-to-Projected-FCF | 0.44 | |||||
Earnings Yield (Greenblatt) % | -11.91 | |||||
FCF Yield % | 16.99 | |||||
Forward Rate of Return (Yacktman) % | -6.94 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
HLS Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 56.201 | ||
EPS (TTM) (€) | -0.796 | ||
Beta | 1.02 | ||
Volatility % | 76.27 | ||
14-Day RSI | 28.94 | ||
14-Day ATR (€) | 0.077555 | ||
20-Day SMA (€) | 3.127 | ||
12-1 Month Momentum % | 11.33 | ||
52-Week Range (€) | 2.16 - 4.56 | ||
Shares Outstanding (Mil) | 31.81 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
HLS Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
HLS Therapeutics Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
HLS Therapeutics Inc Frequently Asked Questions
What is HLS Therapeutics Inc(FRA:74D)'s stock price today?
When is next earnings date of HLS Therapeutics Inc(FRA:74D)?
Does HLS Therapeutics Inc(FRA:74D) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |